Advertisement

Topics

Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy

2014-08-27 03:12:37 | BioPortfolio

Summary

MERIT-NHL as an addendum to the International Registry of Radioimmunotherapy (RIT registry) pooling clinical data of patients who suffered from a non-Hodgkin´s lymphoma also includes the documentation of the respective FDG-PET and CT-image files in an online archive.

Based on these documented clinical and imaging data, the MERIT study group centrally performs an intra- as well as interindividual evaluation of follicular CD20+ lymphoma lesions before and after radioimmunotherapy. According to this, the aim of the MERIT-NHL study is to prospectively identify yet unknown patient- and lesion specific prognostic factors predicting patient´s outcome in line with the therapeutic modality radioimmunotherapy.

Study Design

Time Perspective: Prospective

Conditions

Follicular Lymphoma

Location

Dept. of Nuclear Medicine, Saarland University Hospital
Homburg (Saar)
Saarland
Germany
66421

Status

Recruiting

Source

University Hospital, Saarland

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:37-0400

Clinical Trials [1582 Associated Clinical Trials listed on BioPortfolio]

A Study of Enzastaurin in Patients With Follicular Lymphoma

To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in patients with Follicular Lymphoma.

A Study for Patients With Non-Hodgkin's Lymphomas

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and A...

Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL) and evaluate the ...

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

This observational study will evaluate the safety and efficacy of MabThera/Ritux an (rituximab) in previously untreated patients with follicular lymphoma. Data w ill be collected for 3 yea...

An Italian Experience on Grade 3b Follicular Lymphoma

Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma. Also an histolo...

PubMed Articles [1169 Associated PubMed Articles listed on BioPortfolio]

Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma.

Reduced lymphotoxin-beta production by tumour cells is associated with loss of follicular dendritic cell phenotype and diffuse growth in follicular lymphoma.

Cytokine production is essential for follicular dendritic cell (FDC) maintenance and organization of germinal centres. In follicular lymphoma, FDCs are often disarrayed and may lack antigens indicativ...

Intramuscular Follicular Lymphoma.

We present an interesting image of a painless growing mass of the right arm in a 76-year-old man. A musculoskeletal MRI of the right arm showed a 7.5 × 3-cm homogeneous, well-defined mass, elongated ...

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan ...

Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma.

Is rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma associated with improved outcomes?

Medical and Biotech [MESH] Definitions

Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.

The B-cell leukemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.

The period of the MENSTRUAL CYCLE representing follicular growth, increase in ovarian estrogen (ESTROGENS) production, and epithelial proliferation of the ENDOMETRIUM. Follicular phase begins with the onset of MENSTRUATION and ends with OVULATION.

A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.

B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.

More From BioPortfolio on "Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial